VIRX(Delisted)
Viracta TherapeuticsยทNASDAQ
--
--(--)
VIRX Profile
Viracta Therapeutics, Inc.
A biopharmaceutical company that developing targeted inhibitors for the treatment of blood and solid cancers
2533 S Coast Hwy 101, Suite 210, Cardiff, California 92007
--
Viracta Therapeutics, Inc., was incorporated in Delaware on February 10, 1998. Its subsidiaries are mainly located in South San Francisco, California. Viracta is a precision oncology company that targets virus-related malignancies. Viracta's proprietary investigational drug, Nanatinostat, is currently being evaluated in Phase 2 clinical trials in EBV-positive lymphoma in combination with the antiviral drug valganciclovir as an oral combination therapy. Viracta is applying this induced synthetic lethal approach to malignancies associated with EBV, such as nasopharyngeal cancer, gastric cancer and viral-associated cancers.
